These data provide clear evidence for the potency of glucagon pharmacology to tune the maximal weight loss that can be achieved pre-clinically, and eventual clinical testing will provide the translational evidence of the power in harnessing these three pharmacologies for patients with obesity. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.